Cargando…

Dapagliflozin plus exenatide on patients with type 2 diabetes awaiting bariatric surgery in the DEXBASU study

The glucagon-like peptide-1 receptor agonist family together with the renal sodium/glucose cotransporter-2 inhibitors have garnered interest as potential therapeutic agents for subjects with type 2 diabetes and obesity. In these patients, bariatric surgery is indicated based in a BMI ≥ 35 kg/m(2). A...

Descripción completa

Detalles Bibliográficos
Autores principales:	López-Cano, Carolina, Santos, Maria Dolores, Sánchez, Enric, Martí, Raquel, Bueno, Marta, Gutiérrez-Carrasquilla, Liliana, Lecube, Albert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8881618/ https://www.ncbi.nlm.nih.gov/pubmed/35217772 http://dx.doi.org/10.1038/s41598-022-07250-z

Ejemplares similares

Dynamics of Anthropometric Indices in a Large Paired Cohort With 10 Years of Follow-Up: Paving the Way to Sarcopenic Obesity
por: Santos, Maria-Dolores, et al.
Publicado: (2020)

The influence of sleep apnea syndrome and intermittent hypoxia in carotid adventitial vasa vasorum
por: López-Cano, Carolina, et al.
Publicado: (2019)

Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION‐8 randomized controlled trial
por: Frías, Juan P., et al.
Publicado: (2018)

Effect of Subcutaneous Insulin on Spirometric Maneuvers in Patients with Type 1 Diabetes: A Case-Control Study
por: Sánchez, Enric, et al.
Publicado: (2020)

Effect of Type 2 Diabetes Mellitus on the Hypoxia-Inducible Factor 1-Alpha Expression. Is There a Relationship with the Clock Genes?
por: López-Cano, Carolina, et al.
Publicado: (2020)

Combined antidiabetic benefits of exenatide and dapagliflozin in diabetic mice
por: Tatarkiewicz, K, et al.
Publicado: (2014)

Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION‐8 study
por: Jabbour, Serge A., et al.
Publicado: (2018)

Sympathetic Hyperactivity and Sleep Disorders in Individuals With Type 2 Diabetes
por: López-Cano, Carolina, et al.
Publicado: (2019)

Effect of Glucose Improvement on Nocturnal Sleep Breathing Parameters in Patients with Type 2 Diabetes: The Candy Dreams Study
por: Gutiérrez-Carrasquilla, Liliana, et al.
Publicado: (2020)

Exenatide and Dapagliflozin Combination Enhances Sertoli Cell Secretion of Key Metabolites for Spermatogenesis
por: Ribeiro, João C., et al.
Publicado: (2022)

The Meaning of Awaiting Bariatric Surgery Due to Morbid Obesity
por: Engström, My, et al.
Publicado: (2011)

A Clinical-Genetic Score for Predicting Weight Loss after Bariatric Surgery: The OBEGEN Study
por: Ciudin, Andreea, et al.
Publicado: (2021)

Assessment of dyspneic sensation in patients with type 2 diabetes
por: Mizab, Chadia, et al.
Publicado: (2023)

Effects of Mediterranean Diet and Physical Activity on Pulmonary Function: A Cross-Sectional Analysis in the ILERVAS Project
por: Gutiérrez-Carrasquilla, Liliana, et al.
Publicado: (2019)

Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes
por: Gastaldelli, Amalia, et al.
Publicado: (2019)

Health status, quality of life, and satisfaction of patients awaiting multidisciplinary bariatric care
por: Padwal, Raj S, et al.
Publicado: (2012)

Randomized Clinical Trial to Evaluate the Morphological Changes in the Adventitial Vasa Vasorum Density and Biological Markers of Endothelial Dysfunction in Subjects with Moderate Obesity Undergoing a Very Low-Calorie Ketogenic Diet
por: Sánchez, Enric, et al.
Publicado: (2021)

A Randomized Controlled Trial of Dapagliflozin Plus Once-Weekly Exenatide Versus Placebo in Individuals with Obesity and Without Diabetes: Metabolic Effects and Markers Associated with Bodyweight Loss
por: Pereira, Maria J., et al.
Publicado: (2018)

Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year
por: Lundkvist, Per, et al.
Publicado: (2017)

Effects of Dapagliflozin and Combination Therapy With Exenatide on Food-Cue Induced Brain Activation in Patients With Type 2 Diabetes
por: van Ruiten, Charlotte C, et al.
Publicado: (2022)

Brain Activation in Response to Low-Calorie Food Pictures: An Explorative Analysis of a Randomized Trial With Dapagliflozin and Exenatide
por: van Ruiten, Charlotte C., et al.
Publicado: (2022)

Beyond the Glycaemic Control of Dapagliflozin: Microangiopathy and Non-classical Complications
por: Bellido, Virginia, et al.
Publicado: (2022)

Beyond the Glycaemic Control of Dapagliflozin: Impact on Arterial Stiffness and Macroangiopathy
por: González-Clemente, José M., et al.
Publicado: (2022)

Contraceptive practices and menstrual patterns in women aged 18–50 years awaiting bariatric surgery
por: Graham, Yitka N H, et al.
Publicado: (2018)

Prehabilitation of overweight and obese patients with dysglycemia awaiting bariatric surgery: Predicting the success of obesity treatment
por: Cigrovski Berkovic, Maja, et al.
Publicado: (2022)

Dissimilar Impact of a Mediterranean Diet and Physical Activity on Anthropometric Indices: A Cross-Sectional Study from the ILERVAS Project
por: Sánchez, Marta, et al.
Publicado: (2019)

Awaiting the “catharsis”
por: Yfantopoulos, John
Publicado: (2020)

Obesity, a Diet-Induced Inflammatory Disease
por: Lecube, Albert, et al.
Publicado: (2019)

Pregnancy after bariatric surgery: improving outcomes for mother and child
por: González, Irene, et al.
Publicado: (2016)

Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add‐on to metformin in patients with type 2 diabetes
por: Müller‐Wieland, Dirk, et al.
Publicado: (2018)

A randomised, controlled, double blind study to assess mechanistic effects of combination therapy of dapagliflozin with exenatide QW versus dapagliflozin alone in obese patients with type 2 diabetes mellitus (RESILIENT): study protocol
por: Brown, Emily, et al.
Publicado: (2021)

Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial
por: van Ruiten, Charlotte C., et al.
Publicado: (2022)

Usefulness of an accelerated transoesophageal stress echocardiography in the preoperative evaluation of high risk severely obese subjects awaiting bariatric surgery
por: Legault, Sylvie, et al.
Publicado: (2010)

Impairments of postural control, functional performance and strength in morbidly obese patients awaiting bariatric surgery in comparison to healthy individuals
por: Eckstein, Max Lennart, et al.
Publicado: (2018)

Impact of a Preoperative Exercise Program on General Fitness in Patients Awaiting Bariatric Surgery: A Pilot Randomized Trial
por: Hardy, Krista, et al.
Publicado: (2022)

Prediabetes Is Associated with Increased Prevalence of Sleep-Disordered Breathing
por: Sánchez, Enric, et al.
Publicado: (2022)

Pancreatitis Incidence in the Exenatide BID, Exenatide QW, and Exenatide QW Suspension Development Programs: Pooled Analysis of 35 Clinical Trials
por: Vetter, Marion L., et al.
Publicado: (2019)

The Role of Morbid Obesity in the Promotion of Metabolic Disruptions and Non-Alcoholic Steatohepatitis by Helicobacter Pylori
por: Lecube, Albert, et al.
Publicado: (2016)

Clinical opportunity awaits at the intersection of genomics and brain imaging
por: Makowski, Carolina, et al.
Publicado: (2022)

Population pharmacokinetics of exenatide
por: Cirincione, Brenda, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_s81o06ccdn85e0orm7e60gu6ud